Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 09, 2023 06:30 ET | Source: Veru Inc.

Veru Reports Fiscal 2023 First Quarter Financial Results

Sabizabulin for moderate to severe COVID-19 under review for potential emergency authorization by multiple global regulatory agencies Presented late-breaker oral presentation at IDWeek; sabizabulin...
January 26, 2023 08:30 ET | Source: Veru Inc.

Veru to Report Fiscal 2023 First Quarter Financial Results on February 9, 2023

MIAMI, FL, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for...
January 10, 2023 08:30 ET | Source: Veru Inc.

Veru Announces Appointment of Dr. David D. Ho as Chairman of its Infectious Disease Scientific Advisory Board

MIAMI. FL, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for...
December 05, 2022 06:30 ET | Source: Veru Inc.

Veru Reports Fiscal 2022 Fourth Quarter and Full Year Financial Results

U.S. FDA reviewing EUA application for sabizabulin to treat hospitalized COVID-19 patients at high risk for ARDS European Medicines Agency’s (EMA) Emergency Task Force reviewing sabizabulin for...
November 28, 2022 08:30 ET | Source: Veru Inc.

Veru to Report Fiscal 2022 Fourth Quarter and Full Year Financial Results on December 5, 2022

MIAMI, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for...
November 09, 2022 20:55 ET | Source: Veru Inc.

Veru Provides Update on FDA Advisory Committee Meeting Regarding Emergency Use Authorization of Sabizabulin to Treat Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome

MIAMI, FL, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for...
October 24, 2022 08:30 ET | Source: Veru Inc.

Veru Announces Late-Breaker Oral Presentation of Sabizabulin Treatment for Hospitalized Adults with COVID-19 on Supplemental Oxygen at Infectious Disease Week 2022

MIAMI, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for...
October 13, 2022 08:30 ET | Source: Veru Inc.

Veru to Present Late-Breaker Oral Presentation of Sabizabulin Treatment for Hospitalized Adults with COVID-19 on Supplemental Oxygen at Infectious Disease Week 2022

MIAMI, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for...
October 04, 2022 16:30 ET | Source: Veru Inc.

Veru Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

MIAMI, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for...
September 21, 2022 08:30 ET | Source: Veru Inc.

Veru to Participate in the Cantor Oncology, Hematology & HemeOnc Conference on September 28th, 2022

MIAMI, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right